Base de dados : LILACS
Pesquisa : D04.210.500.365.415.248 [Categoria DeCS]
Referências encontradas : 551 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 56 ir para página                         

  1 / 551 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-959521
Autor: Adauy, Arlette; Sandoval, Jorge; Ríos, Rafael; Cartes, Alejandra; Salinas, Hugo.
Título: Terapia hormonal en la transición femenino a masculino (ftm), androgénica, para trans masculino o para hombre transgénero / Hormone Therapy in Female to Male Transition (FTM), Androgenic, Trans Male, or Transgender Male
Fonte: Rev. chil. obstet. ginecol. (En línea);83(3):318-328, jun. 2018. tab.
Idioma: es.
Resumo: RESUMEN La transexualidad, o el ser transgénero según la nomenclatura actual, describe a personas que persistentemente buscan ser aceptados como miembros del sexo opuesto, desean cambiar sus caracteres sexuales primarios y/o secundarios a través de intervenciones médicas tanto hormonales como quirúrgicas para feminizarse o masculinizarse. (Tabla 1) Esta discordancia entre su "sexo biológico" y "psicológico" genera estrés clínicamente significativo con rechazo profundo al cuerpo del sexo anatómico, al género asignado al nacer y, por ende, alteración persistente en el funcionamiento diario (mayor a 6 meses), se denomina disforia de género, sienten que nacieron en el "cuerpo equivocado". El objetivo de la intervención médica es mejorar la disforia de género y, por consiguiente, mejora el bienestar y la calidad de vida de las personas trans. En Revista de la Sociedad Chilena de Obstetricia y Ginecología Infantil y de la Adolescencia, recientemente hemos publicado dos artículos de revisión sobre la introducción a la Hormonoterapia en personas transexuales, objetivos de la terapia, transición en la adolescencia, y la transición masculino a femenino, por lo que éste escrito se concentrará sólo en la Terapia Hormonal de la transición femenino a Masculino (FTM), son personas que transitan de Mujer a Hombre, o transgénero masculino o trans masculino. (1,2)

ABSTRACT Transsexuality, or being transgender according to the current nomenclature, describes people who persistently seek to be accepted as members of the opposite sex, wish to change their primary and / or secondary sexual characteristics through both hormonal and surgical medical interventions to feminize or masculinize themselves. (Table 1) This discordance between their "biological" and "psychological" sex, generates clinically significant stress with profound rejection of the body of the anatomical sex, the gender assigned at birth and, therefore, persistent alteration in daily functioning (more than 6 months), is called gender dysphoria feel that they were born in the "wrong Body". The goal of medical intervention is to improve gender dysphoria and, consequently, improve the well-being and quality of life of transgender people. In the Journal of the Chilean Society of Obstetrics and Child and Adolescent Gynecology, we have recently published two review articles on the introduction of Hormonotherapy in transgender people, goals of therapy, transition in adolescence, and the male-to-female transition, so this paper will focus only on Hormonal Therapy of the female to male transition (FTM), are people who transit from woman to man, or male trans, male transgender. (1,2)
Descritores: Pessoas Transgênero/psicologia
Disforia de Gênero/psicologia
Hormônios/uso terapêutico
-Ajustamento Social
Estradiol/uso terapêutico
Procedimentos de Readequação Sexual
Identidade de Gênero
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: CL126.2 - Biblioteca Médica Dr. Profesor Hernán Alessandri R.


  2 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-838967
Autor: Da, Yun-Meng; Niu, Kai-Yu; Liu, Shu-Ya; Wang, Ke; Wang, Wen-Juan; Jia, Jing; Qin, Li-Hua; Bai, Wen-Pei.
Título: Does Cimicifuga racemosa have the effects like estrogen on the sublingual gland in ovariectomized rats?
Fonte: Biol. Res;50:11, 2017. graf.
Idioma: en.
Projeto: National Natural Science Foundation of China; . National Natural Science Foundation of China.
Resumo: BACKGROUND: Cimicifuga racemosa is one of the herbs used for the treatment of climacteric syndrome, and it has been cited as an alternative therapy to estrogen. Apart from hectic fevers, dyspareunia and so on, dry mouth also increase significantly after menopause. It has not yet been reported whether C. racemosa has any impact on the sublingual gland, which may relate to dry mouth. In an attempt to determine this, we have compared the effects of estrogen and C. racemosa on the sublingual gland of ovariectomized rats. RESULTS: HE staining showed that the acinar cell area had contracted and that the intercellular spaces were broadened in the OVX (ovariectomized rats) group, while treatment with estradiol (E2) and iCR (isopropanolic extract of C. racemosa) improved these lesions. Transmission electron microscopy showed that rough endoplasmic reticulum expansion in mucous and serous acinar epithelial cells and apoptotic cells was more commonly seen in the OVX group than in the SHAM (sham-operated rats) group. Mitochondria and plasma membrane infolding lesions in the striated ducts were also observed. These lesions were alleviated by both treatments. It is of note that, in the OVX + iCR group, the volume of mitochondria in the striated duct was larger than in other groups. Immunohistochemical staining showed that the ratio of caspase-3 positive cells was significantly increased in the acinar cells of the OVX group compared with the SHAM group (p < 0.05); and the MA (mean absorbance) of caspase-3 in the striated ducts also increased (p < 0.05). Estradiol decreased the ratio of caspase-3 positive cells and the MA of caspase-3 in striated ducts significantly (p < 0.05). ICR also reduced the ratio of caspase-3 positive cells and the MA in the striated ducts (p < 0.05), but the reduction of the MA in striated ducts was inferior to that of the OVX + E2 group (p < 0.05). CONCLUSION: Both estradiol and iCR can inhibit subcellular structural damage, and down-regulate the expression of caspase-3 caused by ovariectomy, but their effects were not identical, suggesting that both drugs confer a protective effect on the sublingual gland of ovariectomized rats, but that the specific location and mechanism of action producing these effects were different.
Descritores: Glândula Sublingual/efeitos dos fármacos
Extratos Vegetais/farmacologia
Ovariectomia
Estradiol/farmacologia
Estrogênios/farmacologia
-Fatores de Tempo
Xerostomia/prevenção & controle
Climatério/efeitos dos fármacos
Imuno-Histoquímica
Regulação para Baixo
Terapia de Reposição de Estrogênios/métodos
Reprodutibilidade dos Testes
Resultado do Tratamento
Ratos Sprague-Dawley
Apoptose/efeitos dos fármacos
Microscopia Eletrônica de Transmissão
Caspase 3/análise
Caspase 3/efeitos dos fármacos
Células Acinares/efeitos dos fármacos
Limites: Animais
Feminino
Ratos
Tipo de Publ: Estudo de Avaliação
Responsável: CL1.1 - Biblioteca Central


  3 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1153082
Autor: Çolak, Eser; Ulusoy, Mahmut Oğuz; Ceran, Mehmet Ufuk; Taşdemir, Ümit; Kal, Ali; Özçimen, Emel Ebru.
Título: Evaluation of the tear parameters of ovulation induction patients in a short time period with anterior segment optical coherence tomography / Avaliação dos parâmetros lacrimais de pacientes submetidas à indução de ovulação por curto período pela tomografia de coerência óptica do segmento anterior
Fonte: Arq. bras. oftalmol;83(6):511-516, Nov.-Dec. 2020. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: The effects of sex steroid hormones on tearparameters are known. Theaim of this studywas to examine the effects on tear parameters during exposure to high-dose sex steroids in a short period of time. Methods: Forty patients who were admitted to the infertility clinic of our hospital and planned to undergo ovulation induction with exogenous gonadotropins were included in our study. Prior tothe initiation of ovulation induction, the basal levels of estradiol were measured on day 3 of the menstrual cycle and ophthalmologic examinations were performed by the ophthalmology department of our hospital. The estradiol levels were-measured on the day ofovulation induction usinghuman chorionic gonadotropin and compared with basal estra­diol; eye examinations were also repeated. Result: Forty women with reproductive period and average age of 33.3 ± 4.2 years were included in this study. Basal levels of estradiol were significantly (p<0.001) higher after ovulation induction than before induction. The scores in the break-up timeand after induction were 6.2 ± 2.8 sn and 8.4 ± 1.4 sn, respectively. The values of Schirmer's test were 14.3 ± 7.1 mm and 20.6 ± 6.2 mm before and after induction, respectively. Both values were significantly higher after ovulation induction (p<0.001; p=0.001, respectively). Conclusion: We observed impro­vemet in tear function tests following the use of estradiol even for a limited time.The use of estradiol during menopause may improve dry eye symptoms in patients.

RESUMO Objetivo: Os efeitos dos hormônios esteróides se­xuais nos parâmetros lacrimais são conhecidos. O objetivo deste estudo foi examinar como os efeitos nos parâmetros lacrimais durante a exposição a altas doses de esteróides sexuais em um curto período de tempo. Métodos: Quarenta pacientes que foram admitidas na clínica de infertilidade do nosso hospital e planejavam a indução de ovulação por gonadotropinas exógenas. Antes do início da indução da ovulação, os níveis basais de estradiol foram medidos no terceiro dia do ciclo menstrual e os exames oftalmológicos foram efetuados pelo Departamento de Oftalmologia do nosso hospital. Os níveis de estradiol foram medidos no dia da indução da ovulação usando gonadotrofina coriónica humana e comparados aos estradiol basal; exames oftalmológicos também foram repetidos. Resultado: Quarenta mulheres com período reprodutivo e idade média de 33,3 ± 4,2 anos foram incluídas neste estudo. Os níveis basais de estradiol foram significativamente maiores (p<0,001) após a indução da ovulação do que antes desta. Os resultados dos testes de ruptura do filme lacrimal e após a indução foi de 6,2 ± 2,8 s e 8,4 ± 1,4 s respectivamente. Os valores do teste de Schirmer foram 14,3 ± 7,1 mm e 20,6 ± 6,2 mm, respectivamente antes e depois da indução. Ambos os valores foram significativamente maiores após a indução da ovulação (p<0,001; p=0,001 respectivamente). Conclusão: Observamos uma melhora nos testes de função lacrimal após o uso de estradiol, mesmo por tempo limitado. O uso de estradiol durante a menopausa poderá melhorar os sintomas do olho seco em pacientes.
Descritores: Síndromes do Olho Seco
Tomografia de Coerência Óptica
Estradiol
-Indução da Ovulação
Lágrimas
Limites: Humanos
Feminino
Adulto
Responsável: BR1.1 - BIREME


  4 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Mendonça, Berenice Bilharinho de
Texto completo
Id: biblio-890760
Autor: Cunha, Flávia Siqueira; Domenice, Sorahia; Sircili, Maria Helena Palma; Mendonca, Berenice Bilharinho de; Costa, Elaine Maria Frade.
Título: Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women
Fonte: Clinics;73:e86, 2018. tab.
Idioma: en.
Projeto: CNPq; . CNPq.
Resumo: OBJECTIVE: The ideal dosage of cross-sex hormones remains unknown. The aim of this study was to evaluate the luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin levels after low-dose estrogen therapy with or without cyproterone acetate in transgender women. METHODS: The serum hormone and biochemical profiles of 51 transgender women were evaluated before gonadectomy. Hormone therapy consisted of conjugated equine estrogen alone or combined with cyproterone acetate. The daily dose of conjugated equine estrogen was 0.625 mg in 41 subjects and 1.25 mg in 10 subjects, and the daily dose of cyproterone acetate was 50 mg in 42 subjects and 100 mg in one subject. RESULTS: Estrogen-only therapy reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 731.5 to 18 ng/dL, 6.3 to 1.1 U/L and 9.6 to 1.5 U/L, respectively. Estrogen plus cyproterone acetate reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 750 to 21 ng/dL, 6.8 to 0.6 U/L and 10 to 1.0 U/L, respectively. The serum levels of luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin in the patients treated with estrogen alone and estrogen plus cyproterone acetate were not significantly different. The group receiving estrogen plus cyproterone acetate had significantly higher levels of gamma-glutamyltransferase than the group receiving estrogen alone. No significant differences in the other biochemical parameters were evident between the patients receiving estrogen alone and estrogen plus cyproterone acetate. CONCLUSION: In our sample of transgender women, lower estrogen doses than those usually prescribed for these subjects were able to adjust the testosterone and estradiol levels to the physiological female range, thus avoiding high estrogen doses and their multiple associated side effects.
Descritores: Testosterona/sangue
Acetato de Ciproterona/administração & dosagem
Estradiol/sangue
Estrogênios/administração & dosagem
Pessoas Transgênero
Antagonistas de Androgênios/administração & dosagem
-Prolactina/sangue
Hormônio Luteinizante/sangue
Estudos Retrospectivos
Relação Dose-Resposta a Droga
Interações Medicamentosas
Estrogênios/sangue
Hormônio Foliculoestimulante/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Tipo de Publ: Research Support, Non-U.S. Gov't
Ensaio Clínico
Responsável: BR1.1 - BIREME


  5 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1056478
Autor: Lima-Pansini, Livia Fiorim de; Lima, Nayra de Souza Carvalho; Guss, Natan Oliveira; Alves, Izabela Sinara Silva; Gama-de-Souza, Letícia Nogueira da; Gracelli, Jones Bernardes; Pacheco, Marcos da Silva; Coburn, Karla Loureiro Almeida.
Título: Analysis of Estrogen Effects on Eruption of Rat Molars / Análisis de los Efectos del Estrógeno en la Erupción de Molares de Rata
Fonte: Int. j. odontostomatol. (Print);13(4):418-427, dic. 2019. graf.
Idioma: en.
Projeto: To Espirito Santo Research Foundation.
Resumo: ABSTRACT: Tooth eruption requires resorption of the alveolar bone interposed between the tooth germ and the oral mucosa (coronal bone). The cells responsible for bone resorption are the osteoclasts and their activity can be reduced or inactivated by estrogen hormone. We aimed to investigate the effects of estrogen on the process of tooth eruption in rats. Thirty-three Wistar rats, aged two-to-17-days, were divided into control, sham and estrogen-treated groups. After daily injections with estrogen, the animals were euthanized and the jaws removed and processed for histological analysis. We performed clinical examination, morphological analysis, quantification of the number of osteoclasts on the surface of the coronal bone and immunohistochemical analysis of estrogen receptor type alpha (ERα). Estrogen therapy was effective, which could be confirmed by the higher estrogen plasma levels on treated animals. However, it had no effect on tooth development or tooth eruption. Progressive bone resorption was observed and the number of osteoclasts on coronal bone was not affected on hormoneinjected animals, allowing tooth to erupt at the same time observed in untreated animals. Immunohistochemistry for ERα confirmed the presence of this type of receptor in osteoclasts, osteoblasts and osteocytes. Taken together, our results showed that estrogen stimulation was not sufficient to decrease the number of osteoclasts on the coronal bone, supporting the idea that, although estrogen may have a protective activity on bone resorption, this may not apply to the alveolar bone that is meant to be resorbed during eruptive process.

RESUMEN: La erupción dental requiere la resorción del hueso alveolar interpuesto entre el germen dental y la mucosa oral (hueso coronal). Las células responsables de la resorción ósea son los osteoclastos y su actividad puede reducirse o inactivarse por la hormona del estrógeno. Objetivos: apuntamos a investigar los efectos del estrógeno en el proceso de la erupción dental en ratas. Treinta y tres ratas Wistar, de dos a 17 días de edad, se dividieron en grupos de control, Sham y se trataron con estrógenos. Los animales fueron eutanizados después del tratamento con estrógeno y se procesaron las mandíbulas para el análisis histológico. Se realizó el examen clínico, el análisis morfológico, la cuantificación del número de osteoclastos en la superficie del hueso coronal y el análisis inmunohistoquímico del tipo de receptor de estrógeno alfa (ERα). La terapia de estrógeno fue eficaz, lo que podría ser confirmado por los niveles plasmáticos más altos de estrógeno en los animales tratados. Sin embargo, no se observó ningún efecto sobre el desarrollo de los dientes o la erupción dental. Se observó una resorción ósea progresiva y el número de osteoclastos en el hueso coronal no se vio afectado en los animales inyectados con hormonas, permitiendo que el diente erupcionó durante el mismo período de tiempo observado en animales no tratados. La inmunohistoquímica para el ERα confirmó la presencia de este tipo de receptor en los osteoclastos, osteoblastos y osteocitos. Nuestros resultados mostraron que la estimulación del estrógeno no fue suficiente para reducir el número de osteoclastos en el hueso coronal confirmando que, si bien el estrógeno puede tener una actividad protectora en la resorción ósea, esto puede no se aplica al hueso alveolar que está destinado a ser rerecurrido durante el proceso eruptivo.
Descritores: Erupção Dentária/fisiologia
Reabsorção Óssea/fisiopatologia
Receptores de Estrogênio
Remodelação Óssea/fisiologia
Experimentação Animal
-Osteoclastos
Imuno-Histoquímica/métodos
Análise Estatística
Comissão de Ética
Ratos Wistar
Estradiol/farmacologia
Estrogênios/administração & dosagem
Estrogênios/efeitos adversos
Estrogênios/uso terapêutico
Processo Alveolar/fisiologia
Limites: Animais
Feminino
Ratos
Responsável: CL1.1 - Biblioteca Central


  6 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1133360
Autor: Breithaupt-Faloppa, Ana Cristina; Correia, Cristiano de Jesus; Prado, Carla Máximo; Stilhano, Roberta Sessa; Ureshino, Rodrigo Portes; Moreira, Luiz Felipe Pinho.
Título: 17ß-Estradiol, a potential ally to alleviate SARS-CoV-2 infection
Fonte: Clinics;75:e1980, 2020. graf.
Idioma: en.
Resumo: Considering that female sexual hormones may modulate the inflammatory response and also exhibit direct effects on the cells of the immune system, herein, we intend to discuss the sex differences and the role of estradiol in modulating the lung and systemic inflammatory response, focusing on its possible application as a treatment modality for SARS-CoV-2 patients. COVID-19 patients develop severe hypoxemia early in the course of the disease, which is silent most of the time. Small fibrinous thrombi in pulmonary arterioles and a tumefaction of endothelial were observed in the autopsies of fatal COVID-19 cases. Studies showed that the viral infection induces a vascular process in the lung, which included vasodilation and endothelial dysfunction. Further, the proportions of CD4+ T and CD8+ T lymphocytes were strongly reduced in patients with severe SARS-CoV-2 infection. Estradiol is connected with CD4+ T cell numbers and increases T-reg cell populations, affecting immune responses to infection. It is known that estradiol exerts a protective effect on endothelial function, activating the generation of nitric oxide (NO) via endothelial nitric oxide synthase. Estrogen attenuates the vasoconstrictor response to various stimuli and induces vasodilation in the pulmonary vasculature during stress situations like hypoxia. It exerts a variety of rapid actions, which are initiated after its coupling with membrane receptors, which in turn, may positively modulate vascular responses in pulmonary disease and help to maintain microvascular flow. Direct and indirect mechanisms underlying the effects of estradiol were investigated, and the results point to a possible protective effect of estradiol against COVID-19, indicating that it may be considered as an adjuvant therapeutic element for the treatment of patients affected by the novel coronavirus.
Descritores: Pneumonia Viral/terapia
Infecções por Coronavirus/terapia
Estradiol/uso terapêutico
Betacoronavirus
Imunidade Inata
Inflamação/virologia
-Fatores Sexuais
Pandemias
SARS-CoV-2
COVID-19
Inflamação/tratamento farmacológico
Limites: Humanos
Animais
Masculino
Feminino
Ratos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  7 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950735
Autor: Repsold, Lisa; Mqoco, Thandi; Wolmarans, Elize; Nkandeu, Sandra; Theron, Joji; Piorkowski, Tomek; du Toit, Peet; van Papendorp, Dirk; Joubert, Annie Margaretha.
Título: Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
Fonte: Biol. Res;47:1-7, 2014. ilus, graf.
Idioma: en.
Resumo: BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female's erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.
Descritores: Sulfonamidas/farmacologia
Simulação por Computador
Inibidores da Anidrase Carbônica/farmacologia
Eritrócitos/efeitos dos fármacos
Estradiol/análogos & derivados
Estrenos/farmacologia
Antineoplásicos/farmacologia
-Sulfonamidas/toxicidade
Sulfonamidas/farmacocinética
Temperatura
Inibidores da Anidrase Carbônica/farmacocinética
Disponibilidade Biológica
Microscopia Eletrônica de Varredura
Proteínas de Transporte/farmacologia
Proteínas de Transporte/farmacocinética
Anidrase Carbônica II/efeitos dos fármacos
Pesquisa Qualitativa
Eritrócitos/ultraestrutura
Estradiol/toxicidade
Estradiol/farmacologia
Estradiol/farmacocinética
Estrenos/farmacocinética
Descoberta de Drogas
Hemólise/efeitos dos fármacos
Antineoplásicos/farmacocinética
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Responsável: CL1.1 - Biblioteca Central


  8 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1249591
Autor: Ricardo-da-Silva, Fernanda Yamamoto; Fantozzi, Evelyn Thaís; Rodrigues-Garbin, Sara; Domingos, Helori Vanni; Oliveira-Filho, Ricardo Martins; Vargaftig, Bernardo Boris; Riffo-Vasquez, Yanira; Breithaupt-Faloppa, Ana Cristina; Tavares-de-Lima, Wothan.
Título: Estradiol prevented intestinal ischemia and reperfusion-induced changes in intestinal permeability and motility in male rats
Fonte: Clinics;76:e2683, 2021. graf.
Idioma: en.
Projeto: Fundação de Amparo è Pesquisa do Estado de São Paulo.
Resumo: OBJECTIVES: Ischemia and reperfusion (I/R) in the intestine could lead to severe endothelial injury, compromising intestinal motility. Reportedly, estradiol can control local and systemic inflammation induced by I/R injury. Thus, we investigated the effects of estradiol treatment on local repercussions in an intestinal I/R model. METHODS: Rats were subjected to ischemia via the occlusion of the superior mesenteric artery (45 min) followed by reperfusion (2h). Thirty minutes after ischemia induction (E30), 17β-estradiol (E2) was administered as a single dose (280 μg/kg, intravenous). Sham-operated animals were used as controls. RESULTS: I/R injury decreased intestinal motility and increased intestinal permeability, accompanied by reduced mesenteric endothelial nitric oxide synthase (eNOS) and endothelin (ET) protein expression. Additionally, the levels of serum injury markers and inflammatory mediators were elevated. Estradiol treatment improved intestinal motility, reduced intestinal permeability, and increased eNOS and ET expression. Levels of injury markers and inflammatory mediators were also reduced following estradiol treatment. CONCLUSION: Collectively, our findings indicate that estradiol treatment can modulate the deleterious intestinal effects of I/R injury. Thus, estradiol mediates the improvement in gut barrier functions and prevents intestinal dysfunction, which may reduce the systemic inflammatory response.
Descritores: Traumatismo por Reperfusão/prevenção & controle
Traumatismo por Reperfusão/tratamento farmacológico
Estradiol/farmacologia
-Permeabilidade
Reperfusão
Estrogênios
Intestinos
Isquemia
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  9 / 551 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-978780
Autor: Hermosilla B, Nicolás; Toro, Gonzalo De; Molgó, Montserrat.
Título: Porfiria cutánea tarda: caso clínico / Porphyria cutanea tarda: case report
Fonte: Rev. méd. Chile;146(8):943-946, ago. 2018. graf.
Idioma: es.
Resumo: Porphyria cutanea tarda (PCT) is the most common type of porphyria: it is characterized by blistering lesions, erosions and crusts on the back of the hands, associated with photosensitivity and facial hypertrichosis. It is produced by acquired or hereditary deficiency of the enzyme UROD, fifth enzyme in the chain of production of the Heme group. This causes accumulation of porphyrins in the liver, which are subsequently mobilized to the skin, where lesions are generated by photosensitivity. This deficiency can be exacerbated by multiple causes. We report a 51-year-old female presenting with the characteristic dermal lesions described above, which disappeared when she discontinued her hormone replacement therapy with estradiol and dydrogesterone. Urinary and blood uroporphyrin and hexacarboxyl porphyrins were elevated and plasma ferritin was 479 ng/ml. Hormone replacement therapy was discontinued and phlebotomies were attempted but not tolerated by the patient. The dermic lesions have not relapsed.
Descritores: Porfiria Cutânea Tardia/diagnóstico
Porfiria Cutânea Tardia/induzido quimicamente
Terapia de Reposição Hormonal/efeitos adversos
Didrogesterona/efeitos adversos
Estradiol/efeitos adversos
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  10 / 551 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-641940
Autor: Giovambattista, A; Castrogiovami, D; Spinedi, E.
Título: Efecto de esteroides sexuales sobre la función endocrina adipocitaria e insulinosensibilidad periférica / Effect of sexual steroids over the adipocyte and outlying insulin sensitivity
Fonte: Rev. argent. endocrinol. metab;45(4):149-161, jul.-sep. 2008. graf.
Idioma: es.
Resumo: Es conocido que las hormonas esteroideas sexuales modulan la composición corporal y otras funciones endocrinas. El objetivo del presente trabajo fue estudiar el impacto de la administración de esteroides sexuales sobre la insulinosensibilidad periférica y la función secretora adipocitaria. Grupos de ratas hembra recibieron vehículo (C) o valerato de E2 o propionato de T. Se monitoreó el peso corporal y la ingesta de alimento hasta el día experimental, que fueron sacrificados en condición basal o sometidos a un test de sobrecarga con glucosa. Se evaluaron las concentraciones de leptina, E2, T, glucosa, triglicéridos e insulina (INS). Se ponderó el tejido adiposo parametrial y se aislaron los adipocitos e incubaron con o sin INS. E2 indujo una temprana (p < 0,05) hipofagia, contrariamente, T indujo una moderada (p < 0,05) hiperfagia. Los animales E2 resultaron con menor peso y masa adiposa parametrial que los C (p < 0,05). Los niveles plasmáticos no se modificaron en los animales E2 ni T, salvo el desarrollo de hiperleptinemia en el grupo E2 (p < 0,05). El test de tolerancia a la glucosa mostró (p < 0,05) aumento y disminución en la insulinosensibildad en los animales E2 y T, respectivamente. Finalmente, los adipocitos aislados de animales E2 como los T desarrollaron una disminuida (p < 0,05 vs. C) respuesta a INS. Nuestro estudio pone en evidencia los efectos de E2 y T sobre la sensibilidad a insulina y la función adipocitaria.

Sex hormones are known to modulate body composition and endocrine functions. The aim of the present study was to analyze the impact of sexual steroids administration on the outlying insulin-sensibility and adipocyte secretory function. Groups of female rats received either vehicle (C), E2 valerate, or T propionate. Daily food intake and body weight were recorded until sacrifice under basal conditions or after high glucose load test. Plasma concentrations of leptin, E2, T, glucose, triglycerides, and insulin (INS) were evaluated. The parametrial adipose tissue was pondered and adipocytes were isolated and then incubated with or without INS. E2 induced early hypophagia (p< 0,05); contrarily, T induced moderate hyperphagia (p<0,05). Weight and fatty parametrial mass values were lower for E2- than C-treated animals (p<0,05). Plasma levels remained unmodified either for E2 or T groups, though E2 animals developed hyperleptinemia (p<0.05). The high glucose load test showed increased and decreased insulin-sensitivity (p<0.05) in E2 and T groups, respectively. Finally, E2 and T isolated adipocytes were less sensitive to insulin-induced leptin secretion than C cells (p<0.05 vs. C). Our study reveals that E2 and T hormones affect sensibility to insulin as well as adipocyte functions.
Descritores: Hormônios Esteroides Gonadais/efeitos adversos
Hormônios Esteroides Gonadais/metabolismo
Adipócitos/fisiologia
Insulinas/fisiologia
-Composição Corporal/fisiologia
Leptina/biossíntese
Estradiol/química
Células Endócrinas/fisiologia
Limites: Animais
Feminino
Ratos
Tipo de Publ: Estudo de Avaliação
Conjunto de Dados
Ensaio Clínico Veterinário
Responsável: AR635.1 - FCVyS - Servicio de Información y Documentación



página 1 de 56 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde